 Joshua Solomon
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 46 | 2025 | 660 | 10.130 |
Why?
| | Arthritis, Rheumatoid | 30 | 2025 | 1177 | 5.170 |
Why?
| | Idiopathic Pulmonary Fibrosis | 15 | 2026 | 691 | 2.520 |
Why?
| | Connective Tissue Diseases | 9 | 2022 | 85 | 1.870 |
Why?
| | Pulmonary Fibrosis | 6 | 2025 | 393 | 1.770 |
Why?
| | Dyspnea | 3 | 2025 | 250 | 1.710 |
Why?
| | Tomography, X-Ray Computed | 12 | 2025 | 2772 | 1.450 |
Why?
| | Myositis | 4 | 2025 | 57 | 1.340 |
Why?
| | Immunoglobulin A | 2 | 2020 | 214 | 1.140 |
Why?
| | Autoantibodies | 8 | 2023 | 1512 | 0.900 |
Why?
| | Cough | 1 | 2024 | 123 | 0.800 |
Why?
| | Pyridones | 4 | 2023 | 208 | 0.770 |
Why?
| | Rheumatic Diseases | 4 | 2024 | 98 | 0.770 |
Why?
| | Severity of Illness Index | 4 | 2025 | 2945 | 0.760 |
Why?
| | Symporters | 1 | 2022 | 48 | 0.740 |
Why?
| | Lung Diseases | 2 | 2021 | 783 | 0.690 |
Why?
| | Anxiety Disorders | 1 | 2024 | 370 | 0.680 |
Why?
| | Risk Adjustment | 1 | 2021 | 85 | 0.660 |
Why?
| | Digestive System Surgical Procedures | 1 | 2022 | 112 | 0.650 |
Why?
| | Scleroderma, Systemic | 5 | 2024 | 123 | 0.650 |
Why?
| | Humans | 74 | 2026 | 145491 | 0.640 |
Why?
| | Rectal Neoplasms | 1 | 2022 | 159 | 0.630 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 497 | 0.630 |
Why?
| | Autoimmune Diseases | 4 | 2024 | 469 | 0.620 |
Why?
| | Rheumatology | 4 | 2024 | 133 | 0.610 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 271 | 0.580 |
Why?
| | Coronary Disease | 1 | 2021 | 381 | 0.570 |
Why?
| | Family | 1 | 2023 | 687 | 0.570 |
Why?
| | Aged | 28 | 2026 | 26125 | 0.560 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2023 | 93 | 0.550 |
Why?
| | Respiratory Function Tests | 10 | 2025 | 543 | 0.540 |
Why?
| | Frailty | 1 | 2021 | 204 | 0.540 |
Why?
| | Quality of Life | 3 | 2025 | 3195 | 0.530 |
Why?
| | Middle Aged | 31 | 2026 | 36176 | 0.510 |
Why?
| | Anxiety | 1 | 2024 | 1127 | 0.500 |
Why?
| | Health Personnel | 1 | 2023 | 750 | 0.500 |
Why?
| | Lung | 12 | 2023 | 4103 | 0.490 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 344 | 0.480 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2016 | 34 | 0.480 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2022 | 663 | 0.470 |
Why?
| | Vital Capacity | 8 | 2025 | 292 | 0.440 |
Why?
| | Male | 38 | 2026 | 72817 | 0.430 |
Why?
| | Disease Progression | 7 | 2024 | 2862 | 0.410 |
Why?
| | Female | 38 | 2026 | 78763 | 0.390 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.380 |
Why?
| | Emphysema | 1 | 2013 | 100 | 0.370 |
Why?
| | Sputum | 3 | 2025 | 308 | 0.360 |
Why?
| | Prognosis | 6 | 2021 | 4323 | 0.340 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2011 | 32 | 0.330 |
Why?
| | Smoking | 2 | 2017 | 1468 | 0.320 |
Why?
| | Mortality | 3 | 2021 | 379 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2582 | 0.270 |
Why?
| | Double-Blind Method | 3 | 2023 | 2060 | 0.270 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2017 | 78 | 0.270 |
Why?
| | Fibrosis | 2 | 2023 | 551 | 0.270 |
Why?
| | Risk Factors | 10 | 2026 | 10874 | 0.250 |
Why?
| | Kaplan-Meier Estimate | 5 | 2018 | 974 | 0.250 |
Why?
| | Treatment Outcome | 6 | 2024 | 11831 | 0.240 |
Why?
| | Glucocorticoids | 3 | 2024 | 531 | 0.240 |
Why?
| | Pulmonary Eosinophilia | 1 | 2006 | 27 | 0.240 |
Why?
| | Peptides, Cyclic | 3 | 2023 | 275 | 0.230 |
Why?
| | Narcotics | 1 | 2006 | 58 | 0.230 |
Why?
| | Lung Injury | 2 | 2024 | 241 | 0.230 |
Why?
| | Receptors, Formyl Peptide | 1 | 2025 | 17 | 0.230 |
Why?
| | Neutrophil Activation | 1 | 2025 | 84 | 0.220 |
Why?
| | Radiation Injuries | 1 | 2006 | 149 | 0.210 |
Why?
| | Environmental Pollutants | 1 | 2006 | 143 | 0.210 |
Why?
| | Mendelian Randomization Analysis | 1 | 2024 | 54 | 0.210 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 842 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1755 | 0.200 |
Why?
| | Transforming Growth Factor beta | 2 | 2025 | 475 | 0.200 |
Why?
| | Mucin-5B | 3 | 2025 | 234 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2025 | 636 | 0.200 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 261 | 0.200 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 450 | 0.190 |
Why?
| | Immunomodulation | 1 | 2023 | 99 | 0.190 |
Why?
| | Survival Rate | 6 | 2019 | 2093 | 0.180 |
Why?
| | Rheumatologists | 1 | 2022 | 15 | 0.180 |
Why?
| | Fatigue | 1 | 2024 | 364 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 3 | 2026 | 2355 | 0.180 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6070 | 0.180 |
Why?
| | Plastics | 1 | 2022 | 50 | 0.180 |
Why?
| | Pandemics | 4 | 2024 | 1706 | 0.180 |
Why?
| | Sodium | 1 | 2022 | 198 | 0.170 |
Why?
| | Therapeutic Irrigation | 1 | 2022 | 68 | 0.170 |
Why?
| | Mental Status and Dementia Tests | 1 | 2021 | 26 | 0.170 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1957 | 0.170 |
Why?
| | Adult | 12 | 2025 | 40707 | 0.170 |
Why?
| | Genome-Wide Association Study | 2 | 2026 | 1378 | 0.170 |
Why?
| | Life Expectancy | 1 | 2021 | 72 | 0.160 |
Why?
| | Patient Care | 1 | 2022 | 118 | 0.160 |
Why?
| | HIV Infections | 1 | 2016 | 3189 | 0.160 |
Why?
| | Serum Albumin | 1 | 2021 | 144 | 0.160 |
Why?
| | Rectum | 1 | 2022 | 183 | 0.160 |
Why?
| | Cause of Death | 3 | 2019 | 469 | 0.160 |
Why?
| | United States | 13 | 2024 | 16115 | 0.160 |
Why?
| | Neurosurgical Procedures | 1 | 2022 | 203 | 0.160 |
Why?
| | Attitude | 1 | 2022 | 260 | 0.160 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 202 | 0.150 |
Why?
| | Comorbidity | 2 | 2021 | 1659 | 0.150 |
Why?
| | Geriatric Assessment | 1 | 2021 | 238 | 0.150 |
Why?
| | Sarcoidosis | 2 | 2011 | 163 | 0.140 |
Why?
| | Hemoglobins | 1 | 2021 | 386 | 0.140 |
Why?
| | Aged, 80 and over | 8 | 2021 | 8326 | 0.140 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 34 | 0.140 |
Why?
| | Acute Disease | 1 | 2021 | 1040 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3424 | 0.140 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 308 | 0.130 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1544 | 0.130 |
Why?
| | Case-Control Studies | 5 | 2021 | 3619 | 0.130 |
Why?
| | Glucose | 1 | 2022 | 1039 | 0.130 |
Why?
| | Chaperonins | 1 | 2016 | 6 | 0.130 |
Why?
| | Ether-A-Go-Go Potassium Channels | 1 | 2016 | 6 | 0.130 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2017 | 44 | 0.130 |
Why?
| | Extracellular Traps | 1 | 2017 | 51 | 0.120 |
Why?
| | Pneumocystis carinii | 1 | 2016 | 12 | 0.120 |
Why?
| | Common Variable Immunodeficiency | 1 | 2016 | 25 | 0.120 |
Why?
| | Registries | 1 | 2025 | 2410 | 0.120 |
Why?
| | Biomarkers | 3 | 2025 | 4283 | 0.120 |
Why?
| | Rheumatoid Factor | 1 | 2017 | 178 | 0.120 |
Why?
| | Pedigree | 1 | 2017 | 515 | 0.120 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2950 | 0.120 |
Why?
| | Granuloma | 1 | 2016 | 97 | 0.120 |
Why?
| | Survival Analysis | 2 | 2017 | 1374 | 0.120 |
Why?
| | Thoracic Diseases | 1 | 2015 | 11 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 191 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 427 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1150 | 0.110 |
Why?
| | Critical Care | 1 | 2021 | 703 | 0.110 |
Why?
| | Emergency Medical Services | 1 | 2021 | 697 | 0.100 |
Why?
| | Inflammation | 1 | 2025 | 2883 | 0.100 |
Why?
| | Mortality, Premature | 1 | 2013 | 14 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2022 | 1392 | 0.100 |
Why?
| | Bronchiolitis Obliterans | 1 | 2013 | 61 | 0.090 |
Why?
| | Retrospective Studies | 7 | 2025 | 17269 | 0.090 |
Why?
| | Mycophenolic Acid | 1 | 2013 | 120 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 342 | 0.090 |
Why?
| | Bronchial Diseases | 1 | 2012 | 38 | 0.090 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1332 | 0.090 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2013 | 365 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 839 | 0.090 |
Why?
| | Antigens, Human Platelet | 1 | 2011 | 10 | 0.080 |
Why?
| | Antibodies, Antinuclear | 1 | 2011 | 62 | 0.080 |
Why?
| | Cohort Studies | 2 | 2025 | 5992 | 0.080 |
Why?
| | Hospitalization | 1 | 2021 | 2458 | 0.080 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 325 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1507 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 898 | 0.080 |
Why?
| | Bleomycin | 1 | 2011 | 253 | 0.080 |
Why?
| | Gastroesophageal Reflux | 1 | 2012 | 236 | 0.080 |
Why?
| | Lung Transplantation | 1 | 2013 | 330 | 0.070 |
Why?
| | Risk Assessment | 1 | 2019 | 3759 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2016 | 1487 | 0.070 |
Why?
| | Genomics | 2 | 2025 | 834 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1733 | 0.070 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 249 | 0.070 |
Why?
| | Incidence | 3 | 2021 | 2915 | 0.070 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2012 | 302 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2129 | 0.060 |
Why?
| | Prevalence | 3 | 2021 | 2855 | 0.060 |
Why?
| | Japan | 1 | 2026 | 147 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2025 | 41 | 0.060 |
Why?
| | Mass Screening | 2 | 2024 | 1358 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1247 | 0.060 |
Why?
| | Genetic Loci | 1 | 2026 | 260 | 0.050 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2024 | 10 | 0.050 |
Why?
| | Sjogren's Syndrome | 1 | 2024 | 37 | 0.050 |
Why?
| | Walk Test | 1 | 2024 | 81 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2025 | 227 | 0.050 |
Why?
| | Young Adult | 5 | 2021 | 14192 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 619 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2006 | 426 | 0.050 |
Why?
| | Bronchi | 1 | 2024 | 263 | 0.040 |
Why?
| | Polymyositis | 1 | 2021 | 13 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2023 | 127 | 0.040 |
Why?
| | Dermatomyositis | 1 | 2021 | 24 | 0.040 |
Why?
| | Sex Factors | 3 | 2013 | 2110 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 83 | 0.040 |
Why?
| | Sex Distribution | 2 | 2012 | 387 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 738 | 0.040 |
Why?
| | Biopsy | 2 | 2014 | 1081 | 0.040 |
Why?
| | Neutrophils | 1 | 2025 | 1124 | 0.040 |
Why?
| | Methotrexate | 1 | 2021 | 232 | 0.040 |
Why?
| | Canada | 1 | 2021 | 434 | 0.040 |
Why?
| | Occupations | 1 | 2019 | 50 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2026 | 2146 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 2130 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2018 | 83 | 0.030 |
Why?
| | Forecasting | 1 | 2019 | 391 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 654 | 0.030 |
Why?
| | Hypersplenism | 1 | 2016 | 9 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5426 | 0.030 |
Why?
| | Leukopenia | 1 | 2016 | 33 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2016 | 76 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 404 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1082 | 0.030 |
Why?
| | Arthritis | 1 | 2016 | 96 | 0.030 |
Why?
| | Protein Folding | 1 | 2016 | 279 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 633 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 22485 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 925 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 632 | 0.030 |
Why?
| | Critical Illness | 1 | 2021 | 901 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 743 | 0.030 |
Why?
| | Alberta | 1 | 2013 | 26 | 0.030 |
Why?
| | Radiography | 1 | 2016 | 852 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1853 | 0.020 |
Why?
| | Age Factors | 2 | 2011 | 3340 | 0.020 |
Why?
| | Medicare | 1 | 2018 | 905 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 65 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2012 | 116 | 0.020 |
Why?
| | Signal Transduction | 1 | 2025 | 5202 | 0.020 |
Why?
| | Lung Compliance | 1 | 2011 | 42 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 76 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5891 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 115 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 563 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2010 | 78 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2250 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1500 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 403 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 529 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 453 | 0.020 |
Why?
| | Risk | 1 | 2011 | 917 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1001 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 7197 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1816 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2011 | 779 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 7171 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5989 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 8039 | 0.010 |
Why?
| | Mice | 1 | 2011 | 18338 | 0.010 |
Why?
| | Animals | 1 | 2011 | 38141 | 0.000 |
Why?
|
|
Solomon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|